The most potent criticism of the U.S. chip controls wasn't flawed strategy, but the chronic underfunding and limited capacity of agencies like the Bureau of Industry and Security (BIS) to effectively enforce complex export bans against determined adversaries.

US policymakers debating restrictions on China's biotech sector may be influenced by competition in industries like semiconductors and electric vehicles. This approach is flawed because it fails to recognize that the life sciences industry is fundamentally different, with unique dynamics in innovation, IP, and global collaboration that don't map directly from other technology sectors.

The US biotech industry is divided on collaborating with Chinese firms. A significant group feels trapped in a prisoner's dilemma: they would prefer if everyone stopped working with Chinese companies, but feel forced to engage because if their competitors do, they'll be at a significant disadvantage by opting out.

The updated Biosecure Act replaces a fixed list of sanctioned Chinese firms with a dynamic designation process controlled by the administration. This shifts risk for U.S. biotechs from a known quantity to an unpredictable political process, where any Chinese partner could be deemed a "company of concern" at any time.

Current US legislative focus on restricting capital and IP flow to China's biotech sector may be misdirected. The more pressing national security vulnerability is the heavy US reliance on China for the physical supply chain of drug manufacturing, including inputs and finished products, which remains largely unaddressed.

Increased US political focus on data integrity, national security, and patient protections in Chinese clinical trials introduces significant uncertainty. Biopharma companies relying on China for drug development could face costly delays and new questions about the validity of their data from regulators.

A deep philosophical and financial divide exists within the U.S. biopharma industry regarding China. Some leaders, like Ginkgo Bioworks' CEO, advocate for protectionist investment controls to counter Chinese competition. In contrast, others, like RA Capital's Peter Kolchinsky, argue such walls harm global innovation, revealing a core debate often aligned with financial interests.

Unlike its predecessor, the likely-to-pass Biosecure Act 2.0 doesn't name specific companies like WuXi AppTec. Instead, it grants the administration discretionary power to define "companies of concern" and the resulting market consequences. This ambiguity leaves biopharma companies uncertain about future supply chain partners and market access, creating a prolonged period of strategic risk.

John Crowley, CEO of Bio, argues the best strategy for US biotech dominance is not protectionism. Instead, the focus should be on improving the US's own competitive advantages, like streamlining regulations and lowering innovation costs, to maintain its lead rather than trying to stifle Chinese research.